Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Genesis Therapeutics, a US-based developer of small molecule therapeutics exploiting artificial intelligence technology invented at Stanford University, received $4.1m on Thursday in a seed round led by Andreessen Horowitz that featured Felicis Ventures and unnamed additional investors. Founded earlier in 2019, the spinout will target severe and debilitating diseases using its AI platform, leveraging development partnerships with drug developers. The seed money will help Genesis drive early recruitments focused on scientists, software engineering and artificial intelligence. Genesis Therapeutics builds on…
